Skip to main content
. 2016 Mar 7;126(4):1251–1266. doi: 10.1172/JCI83427

Figure 11. Strategy for targeting doppel-expressing angiogenic tumors.

Figure 11

GAG-based therapeutic material binds with the tumor endothelial marker doppel, which constitutively interacts with surface VEGFR2 in TECs, but not NECs. This subsequently triggers induced internalization of the doppel-VEGFR2 complex and inhibits VEGF signaling and angiogenesis in tumors.